




UNITED STATES PATENT AND TRADEMARK OFFICE


UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
-----------------	-------------	----------------------	---------------------	------------------

10/824,584

04/08/2004

Stephen Hart

20040117.ORI

6640

23595 7590 01/11/2007
NIKOLAI & MERSEREAU, P.A.
900 SECOND AVENUE SOUTH
SUITE 820
MINNEAPOLIS, MN 55402

EXAMINER

EPPS FORD, JANET L

ART UNIT

PAPER NUMBER

1633

SHORTENED STATUTORY PERIOD OF RESPONSE	MAIL DATE	DELIVERY MODE
--	-----------	---------------

31 DAYS

01/11/2007

PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

If NO period for reply is specified above, the maximum statutory period will apply and will expire 6 MONTHS from the mailing date of this communication.

DETAILED ACTION

Election/Restrictions

1. Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted.

Group I. Claims 1, 3-11, 17-26, 31-33, 39 and 41, drawn to a method for suppressing the expression of a selected gene comprising the use of a molecule comprising a nucleic acid binding portion and an expression repressor portion.

Group II. Claims 2-11, 17-26, 31-33, and 40-41 drawn to a method for modulating the expression of a selected gene comprising the use of a molecule comprising a nucleic acid binding portion and a modifying portion.

2. The inventions listed as Groups I and II do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: The identified inventions relate to multiple methods which involve distinct objectives, distinct method steps, distinct materials, and producing distinct outcomes. The multiple methods are therefore considered to encompass multiple categories of invention. The claims are therefore not considered to have unity of invention as per 37 CFR 1.475(b)-(c), which state the following:

(b) An international or a national stage application containing claims to different categories of invention will be considered to have unity of invention if the claims are drawn only to one of the following combinations of categories:

- (1) A product and a process specially adapted for the manufacture of said product; or
- (2) A product and process of use of said product; or
- (3) A product, a process specially adapted for the manufacture of the said

Art Unit: 1633

product, and a use of the said product; or

(4) A process and an apparatus or means specifically designed for carrying out the said process; or

(5) A product, a process specially adapted for the manufacture of the said product, and an apparatus or means specifically designed for carrying out the said process.

(c) If an application contains claims to more or less than one of the combinations of categories of invention set forth in paragraph (b) of this section, unity of invention might not be present.

With the election of either Groups I or II, a further restriction is required as follows:

3. Group III, claim 4, drawn to a method according to claim 1 or 2 wherein the repressor or modifier is all or a portion of a component of a DNA methylase.

4. Group IV, claim 4 drawn to a method according to claim 1 or 2 wherein the repressor or modifier is all or a portion of a component of a polypeptide which binds to or facilitates the recruitment of a DNA methylase complex.

5. Group V, claim 5, drawn to a method according to claim 1 or 2 wherein the repressor or modifier is all or a portion of a component of a histone acetyltransferase.

6. Group VI, claim 5, drawn to a method according to claim 1 or 2 wherein the repressor or modifier is all or a portion of a component of a polypeptide which binds to or facilitates the recruitment of a histone acetyltransferase complex.

Claims 1-2 are linking claims to groups III-VI.

Groups III-VI are patentably distinct from each other because the repressor or modifier group corresponding to each group is structurally and functionally distinct from each other, and each requires a separate search and consideration of the prior art.

7. Additionally, the groups I-VI do not appear to share a special technical feature that makes a contribution over the prior art since the teachings of Buluwella et al. (WO

200102019) appears to render obvious the claimed methods of suppression comprising the use of an effector comprising a complex featuring HDAC.

8. This application contains claims directed to the following patentably distinct species: The claims recite various species of the chromatin inactivation portion, and of the HDAC complex. The species are independent or distinct because each species comprises a distinct chemical structure requiring a separate search and consideration of the prior art. Additionally, claim 33 recites patentably distinct species of host cells that are well known in the art to comprise distinct genomes, express a distinct set of genes, and comprise distinct structures, therefore necessitating a separate search and consideration of the prior art. Moreover, the various species lack unity of invention for the reasons set forth above.

Applicant is required under PCT Rule 13.1 to elect a single disclosed species for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable. Currently, 1-11, 17-25, 31-32, 39-41 are generic.

Applicant is advised that a reply to this requirement must include an identification of the species that is elected consonant with this requirement, and a listing of all claims readable thereon, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered nonresponsive unless accompanied by an election.

9. Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which depend from or otherwise require all the limitations of an allowable generic claim as provided by 37 CFR 1.141. If claims are added after

the election, applicant must indicate which are readable upon the elected species. MPEP § 809.02(a).

10. Applicant is advised that the reply to this requirement to be complete must include (i) an election of a species or invention to be examined even though the requirement be traversed (37 CFR 1.143) and (ii) identification of the claims encompassing the elected invention.

11. The election of an invention or species may be made with or without traverse. To reserve a right to petition, the election must be made with traverse. If the reply does not distinctly and specifically point out supposed errors in the restriction requirement, the election shall be treated as an election without traverse.

Should applicant traverse on the ground that the inventions or species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the inventions or species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C.103(a) of the other invention.

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Claim Objections


12. Claims 12-16 are objected to under 37 CFR 1.75(c) as being in improper form because a multiple dependent claim cannot depend from any other multiple dependent claim. In the instant case, claim 12 (and those claims dependent therefrom) is dependent from claims 3 and 11, however both claims 3 and 11 depend from claims 1 or 2. See MPEP § 608.01(n). Once Applicants have properly amended these claims, applicants are requested to indicate which invention group the amended claims will read on.

Art Unit: 1633

13. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Janet L. Epps-Ford whose telephone number is 571-272-0757. The examiner can normally be reached on M-F, 10:00 AM through 6:30 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Joseph Woitach can be reached on 571-272-0739. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.


Janet L. Epps-Ford, Ph.D.
Primary Examiner
Art Unit 1633

JLE